
PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

CURE spoke with an expert about how psychedelics such as psilocybin may impact patients’ mental health.

An expert explains the new phase of Princess Kate’s cancer journey as she enters remission.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

As someone who has overcome colorectal cancer, I reflect on the support I received from others and vow to continue their legacy of advocacy.

From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.

The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.

The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some patients with MCL.

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

Fifteen years after my own cancer journey, I find myself balancing hope and grief as I support a colleague newly diagnosed with cancer.

Press Release
In February 2016, Angie was diagnosed with de novo metastatic breast cancer after experiencing back and rib pain.

Press Release
In 1992, Milwaukee broadcast journalist Melodie Wilson Oldenburg announced on live television she had been diagnosed with breast cancer.

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy results in the CLEER-001 trial

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Findings show that 81% of posts related to cancer on the social media platform TikTok touted fake cures.

I share how faith, positive affirmations and resilience helped me overcome stage 2 colon cancer and find strength in recovery.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.

As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.

An expert explains the importance of getting a second opinion during a cancer journey.

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors.

At my routine oncology checkup, I regretted not bringing my husband when an unexpected medication changes left me feeling overwhelmed and alone.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.